NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ATGAM General Investigation

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Aplastic Anemia

Interventions: Anti-human thymocyte immunoglobulin, equine

Countries: Japan

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan. The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM. The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with moderate to severe aplastic anemia who receive ATGAM

Exclusion Criteria:

* No exclusion criteria is set out in this study.

Locations (1)

Tokyo, Japan